The US FDA’s neurological devices panel has recommended that the agency approve Medtronic’s Intercept deep brain stimulation (DBS) therapy for epilepsy. The panel voted seven to five in favour of conditional approval of the device as an adjunctive treatment for partial-onset ...
Please Login to read the full article.
